Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running

TLDR

• ARK Invest purchased 56,769 Intellia Therapeutics shares on Thursday, worth roughly $682,000 across two ETFs
• This marks the third straight trading day of ARK accumulating NTLA stock
• Intellia shares have surged 32% year-to-date after dropping 23% in 2025 following a clinical trial death
• The gene-editing firm is developing CRISPR-based treatments for rare diseases
• Analysts rate the stock a Moderate Buy with 38% upside potential from current levels

Cathie Wood’s ARK Invest made headlines again Thursday with another purchase of Intellia Therapeutics stock. The firm bought 56,769 shares across two of its exchange-traded funds.

Intellia Therapeutics, Inc., NTLA

ARKK picked up 48,178 shares while ARKG added 8,591 shares. The combined purchase totaled approximately $682,000.

This represents the third consecutive day ARK has bought Intellia stock. Monday’s purchase totaled 99,292 shares. Tuesday saw another 40,067 shares added to the portfolio.

The stock climbed more than 2% in after-hours trading following news of ARK’s purchase.

Intellia develops gene-editing treatments using CRISPR technology. The clinical-stage biotech company focuses on therapies for rare diseases.

Recent Performance Shows Recovery

The stock has bounced back strongly in 2026. Shares are up over 32% since January 1.

This recovery follows a tough 2025. The stock fell 23% last year after a patient death during a clinical trial. The patient, a male in his 80s, was receiving an experimental treatment called Nexiguran ziclumeran.

The company is testing this therapy for transthyretin amyloidosis with cardiomyopathy. This rare heart disease causes heart failure from defective proteins.

Over the past 12 months, Intellia stock has gained about 26%. Analysts credit steady clinical trial progress and increased investor confidence.

ARK’s Position in Intellia

Intellia ranks as the 23rd largest holding in ARK’s portfolio based on December 31 filings. Within the ARKG genomic fund, it sits among the bottom five positions.

The top three ARKG holdings are Crispr Therapeutics, Tempus AI, and Guardant Health. Despite its lower ranking, ARK Invest continues to add shares.

The three-day buying spree totals nearly 196,000 shares. This sustained accumulation signals confidence in the company’s future.

Wall Street Outlook

Analysts maintain a generally positive stance on the stock. The consensus rating is Moderate Buy based on 22 analyst opinions.

Nine analysts rate it a Buy. Twelve give it a Hold rating. One analyst recommends selling.

The average price target stands at $16.41. This suggests potential upside of roughly 38% from current trading levels.

ARK’s continued purchases align with this bullish outlook. The firm appears confident despite last year’s clinical setback.

Intellia continues advancing its CRISPR programs through various stages of clinical development. The company’s gene-editing platform targets multiple rare diseases.

ARK’s investment strategy focuses heavily on disruptive technologies. Genomics and gene editing represent key themes within the firm’s portfolio strategy.

The sustained buying over three days totals roughly $1.1 million in new Intellia positions. This represents a meaningful bet on the gene-editing sector’s growth potential.

The post Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running appeared first on Blockonomi.